Opinion | Published:

Bioethical accreditation or rating needed to restore trust in pharma

Nature Medicine volume 19, page 261 (2013) | Download Citation

After years of decline in the public eye, drug companies should implment a bioethics accreditation or rating program to help appropriately restore the industry's good name and improve its effectiveness in advancing global health and new treatments.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , & JAMA 302, 977–984 (2009).

  2. 2.

    , & BMJ 344, d7373 (2012).

Download references

Author information

Affiliations

  1. Jennifer E. Miller is president of Bioethics International and a residential fellow in the Edmond J. Safra Center for Ethics at Harvard University in Cambridge, Massachusetts, USA.

    • Jennifer E. Miller

Authors

  1. Search for Jennifer E. Miller in:

Corresponding author

Correspondence to Jennifer E. Miller.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm0313-261

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing